Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate a
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... SoundConnect , an award winning ... announce that Darren Suders has joined the team as ... drive the partner program through innovative offerings, ... , Darren brings more than 10-years of channel telecommunication ... channel operations, from policy development, to partner education and ...
(Date:11/26/2014)... /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il lancio ... di Hi Europe 2014 (dal 2 al 4 dicembre, ... della curcumina con la maggiore biodisponibilità di sempre, con ... approvati dalle norme europee. La curcumina è ... ( Curcuma longa ) che è stata associata con ...
(Date:11/24/2014)... , Belgium , Nov. 24, 2014 ... sciences company focused on developing diagnostic tests for cancer and ... cancer study will be presented at the Science for Business ... Belgium . The data come from VolitionRx,s ... at the Pneumology department of the Centre Hospitalier Universitaire (CHU) ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 2014 ... Dihydrazide Industry is a professional and in-depth research ... Adipic Dihydrazide information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
Breaking Biology Technology:SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3
... , , , BOULDER, ... LENA Autism Screen (LAS) to 91 percent for children 24 to 48 ... is now as accurate or more accurate than other autism screens currently ... http://www.newscom.com/cgi-bin/prnh/20090210/LA69114 ) , , "We,re thrilled with this leap ...
... , , , ... NGSX ), a biopharmaceutical company focused on developing and ... and Chief Executive Officer, is scheduled to present at two upcoming ... Healthcare Conference, to be held September 9 - 11th, 2009, and ...
... , , , ... in vivo imaging from research through medicine, announced today the ... measuring and monitoring apoptosis and cell death in vivo . ... established Annexin labeling standard in in vitro research. It is ...
Cached Biology Technology:Advancement Made in Automatic Autism Screen Increases Accuracy to 91%, Scheduled for Release This Month 2Advancement Made in Automatic Autism Screen Increases Accuracy to 91%, Scheduled for Release This Month 3NeurogesX to Present at Upcoming Fall Conferences 2NeurogesX to Present at Upcoming Fall Conferences 3NeurogesX to Present at Upcoming Fall Conferences 4VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent 2VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent 3
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... like houses, need building materials for their walls. And as ... at just the right moment to protect and allow the ... of the global Ludwig Institute for Cancer Research (LICR) has ... but has also conducted proof-of-principle studies that indicate taking away ...
... coloured males because they are easier to see and ... following her study of fish speciation in the East ... preference and eventually to speciation. , Evolutionary theory ... different characteristics in males. Yet females often pay attention ...
... word pollen to most people and it triggers thoughts of ... Alberta researcher has found an important spin-off for this fine ... from the Department of Biological Sciences at the U of ... pollen on boreal lakes. Rich in nutrients, pollen is an ...
Cached Biology News:Choosy females make colourful males 2
... kit allows for quick and reproducible immunoprecipitation (IP) ... system is more reproducible than regular IPs, which ... A/G agarose without disrupting the agarose bed. The ... Release is reversible, and elution of the immune ...
... locking design in ice/water bath This ... number, created to easily match Cornings ... yet, please order under the old ... service for assistance. ID clarifier: rack ...
Kit containing MACS equipment and reagents for immunopurification of proteins....
... software offers an intuitive, easy-to-use ... control, diverse data handling, and ... Comprehensive functions include data acquisition, ... management in both standalone and ...
Biology Products: